AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01218386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol valerate
Description: Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation.
Study NCT01218386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate
Description: Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation.
Study NCT02660047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide - Placebo
Description: Drug: Liraglutide - Placebo~Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial.
Study NCT01993342 — intervention group
Intervention type: OTHER
Intervention: arthrocentesis
Description: The made a diagnostic arthrocentesis to all patient we included
Study NCT01583400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RESPECT-D
Description: The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.
Study NCT04650828 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate 300 MG
Description: TDF monotherapy was continued for 12 months
Study NCT01256905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 150 mg
Study NCT01583400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RESPECT-D-E (Enhanced)
Description: The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.
Study NCT02705950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal baclofen bolus
Description: An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
Study NCT02705950 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
Study NCT00764075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beutel TM
Description: application of BeutelTM
Study NCT00868816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 cycles of oxaliplatine based adjuvant chemotherapy
Description: oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
Study NCT00868816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8 cycles of oxaliplatine based adjuvant chemotherapy
Description: oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
Study NCT04083274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (Group E)
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded.
Study NCT04083274 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham block group (Group S)
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded
Study NCT00764075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard
Description: standard procedure will be applied but no Beutel TM software
Study NCT00764075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: software Beutel TM
Description: application of BeutelTM to patients data for determination of site of latest contraction
Study NCT04196439 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous epidural analgesia
Description: injection of local anaesthetic into epidural space
Study NCT04196439 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supra-inguinal fascia iliaca compartment block
Description: ultrasound guided injection of local anaesthetic into fascia iliaca compartment
Study NCT02813785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study NCT02813785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered as 75 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 21-day cycle.
Study NCT01610284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
Study NCT01610284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
Study NCT01610284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 100 mg once daily
Study NCT01610284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BKM120 matching placebo
Description: BKM120 matching placebo, once daily
Study NCT04132102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1.
Study NCT03666819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide Fractional Laser
Description: Undergo CO2RE laser therapy
Study NCT03666819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02125734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
Study NCT02125734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
Study NCT03425773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BVAC-B
Description: Autologous B cell and monocyte presenting HER2/neu antigen
Study NCT02704299 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous T cells-Based Immunotherapy
Description: TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.
Study NCT00489008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Cohorts 1 \& 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments~Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments
Study NCT03384667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maekmoondong-tang
Description: MMDT is a Herbal medicine consist of six herbs.
Study NCT03384667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The granules do not contain any active ingredients.
Study NCT02523833 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Salbutamol
Description: Salbutamol after spirometry, plethysmography and forced oscillation technique.
Study NCT03702465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DNA-based dietary intervention
Description: The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the intervention arm, will be provided with a hard-copy of a genetic report, which will explain how their SNPs influence their dietary habits.
Study NCT03702465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DNA-based dietary intervention using an app
Description: The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the exploratory arm, will be given personalised DNA-based dietary advice via the DnaNudge App.
Study NCT03702465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: Standard care for pre-diabetic individuals: dietary advice as per the NICE guidelines for individuals who have pre-diabetes.
Study NCT01449916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified Severe Sepsis Protocol
Description: Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
Study NCT01449916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simplified Severe Sepsis Protocol
Description: Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
Study NCT03120013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal cerebellar and cathodal spinal tDCS
Description: 10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
Study NCT03120013 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cerebellar and sham spinal tDCS
Description: 10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
Study NCT01858194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Description: * The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.~* After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a spiral pattern, see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion).
Study NCT01858194 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VT ablation alone
Description: Placebo arm will receive standard VT ablation using current techniques
Study NCT05928338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-supported, WhatsApp-assisted lifestyle modification intervention
Description: The lifestyle modification intervention, supported by peers and WhatsApp voice calls aimed to assist participants in making dietary modifications, increasing physical activity, and achieve a weight loss of 5% of their initial body weight as well as avoid weight gain. A trained nutritionist delivered the intervention after the baseline assessment individually or in groups that covered six sessions related to dietary modifications, physical activity, set-up goals and action plans, and peer assignments and then once monthly for a year using WhatsApp voice calls to the participants and peers.
Study NCT02747316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable iron isotope 57 (57Fe) labeled iron solution
Description: test meal labeled with 12 mg 57Fe
Study NCT02747316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable iron isotope 58 (58Fe) labeled iron solution
Description: test meal labeled with 12 mg 58Fe
Study NCT01334931 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Large field of view arm
Description: Patients will be allocated in the large field of view arm. Coronary angiography will be performed with large field of view lens (25 cm)
Study NCT01334931 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Medium field of view
Description: Patients will be allocated in the medium field of view arm. Coronary angiography will be performed with medium field of view lens (20 cm)
Study NCT04003727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mcgrath Mac Videolaryngoscope
Description: Patient's laryngoscopy will be done using McGrath Mac video laryngoscope
Study NCT02279810 — intervention group
Intervention type: BEHAVIORAL
Intervention: survey
Description: Survey
Study NCT01978184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Study NCT01978184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abraxane
Study NCT01978184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Study NCT00234884 — intervention group
Intervention type: BIOLOGICAL
Intervention: adalimumab
Description: commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)
Study NCT00507039 — intervention group
Intervention type: PROCEDURE
Intervention: inhalative grass-pollen provocation
Description: Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
Study NCT01177098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost /timolol formulation A fixed combination ophthalmic solution
Description: One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
Study NCT01177098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost/timolol fixed combination ophthalmic solution
Description: One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
Study NCT02555410 — intervention group
Intervention type: DEVICE
Intervention: Brain Sentinel Seizure Detection and Warning System
Description: A sEMG based automated seizure detection and warning system worn on the biceps
Study NCT05121116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness-Based Stress Reduction (MBSR)
Description: Participation in an 8-week MBSR program consisting of pre-recorded mindfulness practices, including a guided body scan in week 1, guided sitting meditation in week 2, mindful yoga practices in week 3 and 4, meditation on difficult emotions in week 5, visualization meditation in week 6, lovingkindness meditation in week 7, and a silent meditation in week 8. Most practices last approximately 30 minutes and participants were encouraged to engage in a mindfulness practice daily or as often as possible. In weeks 2 - 8 participants could choose to alternate the practice introduced each week with practices from previous weeks. Participants had immediate access to all practices but were asked to complete them sequentially and in the order described above over a period of eight weeks. The MBSR program also encourages participants to employ mindfulness in their daily lives, and gives access to educative readings and videos related to the weekly mindfulness practices.
Study NCT01985516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instillation into the urethra
Description: 5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
Study NCT01985516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pouring the gel on the catheter's tip
Description: 5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally).
Study NCT01993342 — intervention group
Intervention type: OTHER
Intervention: ultrasonography of the knee
Description: We explored the affected knee with an ultrasound explanation in order to describe inflammatory changes based on standard examination.
Study NCT02653469 — intervention group
Intervention type: OTHER
Intervention: Augmented ventilation
Description: When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
Study NCT02653469 — intervention group
Intervention type: OTHER
Intervention: Fluid loading
Description: We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
Study NCT02572986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin
Study NCT02572986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin
Study NCT04532333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin 250 MG Injection
Description: Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
Study NCT04532333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
Study NCT00110084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
Study NCT00110084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel protein-bound particles for injectable suspension (albumin-bound)
Description: 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
Study NCT01396499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
Study NCT01771081 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab (or other DME treatment)
Description: Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment
Study NCT04049578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balovaptan
Description: Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.
Study NCT02725840 — intervention group
Intervention type: RADIATION
Intervention: Proton beam radiation therapy.
Description: Proton bean radiation therapy interact differently with tissue with the result that protons are absorbed completely within the tissue instead of primarily passing through the entire body. The maximal depth of penetration is dependent upon the incoming velocity (energy) of the protons. Proton therapy utilizes this property to deliver radiation with very little dose beyond the targeted lesion. The dose-rate will be managed as part of the standard of care.
Study NCT02725840 — intervention group
Intervention type: RADIATION
Intervention: X-ray based radiation therapy
Description: The three-dimensional (3D) mapping of radiation dose distributions permits detailed assessment of local vascular damage as a function of treatment factors of dose, dose-rate. The dose-rate will be managed as part of the standard of care.